Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down - Should You Sell?

Key Points

• Bio-Rad Laboratories' stock price gapped down from $257.75 to $247.05 prior to trading on Wednesday, indicating a 4.2% decline.
• The company's latest earnings report showed an earnings per share of $2.61 with a net margin of 12.50% and return on equity of 4.01%.
• Bio-Rad Laboratories has a market capitalization of $6.72 billion and strong liquidity ratios, with a quick ratio of 3.67 and a current ratio of 5.12.

Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $257.75, but opened at $247.05. Bio-Rad Laboratories shares last traded at $247.05, with a volume of 200 shares.

Bio-Rad Laboratories Stock Performance

The firm has a market cap of $6.72 billion, a PE ratio of 21.06 and a beta of 0.76. The stock's fifty day simple moving average is $250.29 and its 200-day simple moving average is $259.79. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67.

Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $2.61 earnings per share (EPS) for the quarter. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.